A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. (Q38382173)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 February 2016

Language	Label	Description	Also known as
English	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.	scientific article published on 13 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

11

object named as

Laura J Esserman

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

6

object named as

Hope S Rugo

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Michelle E Melisko

7

object named as

Michelle E Melisko

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

5

object named as

Mark M Moasser

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

15

object named as

Pamela N Munster

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Laura J. van't Veer

12

object named as

Laura van't Veer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

13

object named as

Christina Yau

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Alyson Cockerill

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Craig Fancourt

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Emmett Schmidt

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Andrew H Ko

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Katie Kelley

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

W Michael Korn

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Denise M Wolf

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

0 references

publication date

13 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

155

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

521-530

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26875185%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Perturbations of the AKT signaling pathway in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Dose-finding in phase I clinical trials based on toxicity probability intervals.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Modeling precision treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3701-7

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38382173&oldid=2264923939"